8:00 am Registration & Coffee

9:00 am Chair’s Opening Remarks

Assessing Clinical Development of Treg Directed Therapies to Establish Therapeutic Opportunities

9:15 am Regulatory T Cell Therapy for Organ Transplantation and Autoimmune Diseases: The Northwestern Experience

  • James Mathew Professor of Surgery and Microbiology-Immunology; Director of Immune Monitoring Core; Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine


• Provide an overview of the cell therapy program at Northwestern
• Discuss current status of clinical trials of regulatory T cells at our institution
• Discuss ongoing research and development of Treg based therapies for clinical application

9:45 am ATMP-Grade T Regulatory Cells as a Drug for Autoimmune Diseases

  • Piotr Trzonkowski Scientific Advisor, PolTREG; Professor , Medical University of Gdansk


• T regulatory cells (Tregs) are considered a viable option in immunosuppressive treatment in the clinic. First promising clinical experiments and trials with clinical-grade Tregs cultured as advanced therapy medicinal product (ATMP) are completed already
• Hear the long-term results (up to 5 years follow up) of our trials with Tregs in type 1 diabetes in children discussing metabolic and immune background of the patients
• See the first results from the trial with multiple sclerosis as well as future perspectives of the therapy

10:15 am Clinical Trials and Pre-Clinical Studies of T Regulatory Therapy for Graft-versus-Host Disease and Transplantation Tolerance

  • Everett Meyer Assistant Professor of Medicine , Stanford University Medical Center


• Brief report on Stanford trials using T regulatory cells in the hematopoietic stem cell transplantation setting.
• Pre-clinical studies to prevent and treat graft-versus-host disease and promote engraftment with hematopoietic stem cell transplantation.
• Pre-clinical studies of T regulatory cell targeting to transplanted pancreatic islets

10:45 am Morning Refreshments & Speed Networking

11:45 am Panel Discussion: Choosing the Best Indications to Maximize Benefit to Patients

  • Jason Fontenot Senior Vice President, Cell Therapy, Sangamo Therapeutics
  • Everett Meyer Assistant Professor of Medicine , Stanford University Medical Center
  • Robert Levy Scientific Advisor, Pelican Therapeutics; Professor , University of Miami Miller School of Medicine


• Indications that can generate best proof-of concept results and most impact on patients
• Clinical development strategies in various stages of disease progression and patient recruitment early in disease
• Understanding how current standard of care and in vivo Treg approaches can be combined to promote Treg function
• Comparing allogeneic and autologous Treg cell therapy approaches

12:45 pm Translation of in vivo & Preclinical Data of Immune-modulating Therapies


  • Unique signal transduction requirements for Treg function in health and disease state
  • ROCK2 targeting promotes Treg suppressive function via STAT5-dependent mechanism
  • ROCKing Th17/Treg balance in clinics

1:15 pm Lunch & Networking

Optimizing the use of IL-2 to Modulate Treg Activity

2:15 pm Use of Low-Dose IL-2 Therapy to Modulate the Treg Homeostasis & Combinational Therapies to Enhance Treg Function in Transplantation


• IL-2 therapy restores Treg dysfunction induced by calcineurin inhibitors
• Use of low-dose IL-2 to expand endogenous Tregs and achieve transplantation tolerance – Experience from the LITE clinical trial
• Use of ex vivo expanded Tregs in liver transplant recipients (ThRIL clinical trial)
• Preferential expansion of adoptively transferred donor-specific Tregs by IL-2 therapy
• Use of donor-specific CAR-Tregs to promote transplantation tolerance

2:45 pm A Novel IgG-IL2 Mutein to Selectively Activate T Regulatory Cells


• Design and development of an IL-2 mutein showing Treg specificity
• Assessment of Treg pharmacology in vitro and in vivo in non-clinical studies
• Path towards clinical development of Treg therapies using IL-2 muteins

3:15 pm Localized Immunomodulation of Regulatory T cells in the Gut


• Discovery of a novel modified IL-2 that selectively activates Tregs, even at high local concentrations
• Investigation of immunomodulation in tissues
• Demonstration of efficacy in an inflammatory disease model

3:45 pm Afternoon Refreshments & Poster Session

4:45 pm Roundtable Discussions


• More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. This is a dedicated opportunity for you to voice your experience and identify unique solutions.


5:30 pm Chair’s Closing Remarks

5:45 pm Close of Day 1